Pneumonia vaccine study for healthy adults
Treatments studied
Part of Infections clinical trials.
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult (18 years or older).
- You should not have received any pneumococcal vaccine (pneumonia shot) in the past.
- You cannot be taking medications that suppress your immune system, such as steroids or chemotherapy.
- You cannot have a chronic illness that affects your immune system, like HIV or an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This study collects blood samples to help researchers develop better tests. It is for healthy people who have not had a pneumococcal vaccine before.
This trial tests whether giving a pneumococcal vaccine to children hospitalized with severe acute malnutrition can help prevent serious infections. It aims to see if the vaccine is safe and effective in this vulnerable group.
Hear when a new Pneumococcal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.